Significant advances in our understanding of DLBCL have been made in the past decade. Assessment of prognosis by use of the IPI is now in widespread use and facilitates treatment decisions. More recently, microarray technology has refined our ability to formulate prognosis, has generated interesting hypotheses regarding the biology of the disease, and will hopefully allow the design of better treatment strategies for the various subgroups in the near future. DLBCL is a largely chemosensitive disease, and CHOP chemotherapy has long represented an acceptable standard. But relapses are still common and salvage regimens and transplantation are impor-
Was this article helpful?